Press Release 14 November 2025 12:34:00 CET

BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability

Redeye updates its estimates and fair value range following BICO's Q3 2025 report showing a return to organic growth in line with our projections. It also showed a slight beat on sales and adjusted EBITDA compared to our estimates, on account of stronger-than-anticipated Lab Automation sales. BICO trades at an EV/S of 0.5x and an EV/EBITDA of 12x on Redeye's 2026e projections.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. **www.redeye.se/**

Attachments

BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability